FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2581330967> ?p ?o ?g. }

• W2581330967 endingPage "1033" @default.
• W2581330967 startingPage "1023" @default.
• W2581330967 abstract "Objective The objective of this study was to investigate the association of clinical and renal disease activity with circulating sphingolipids in patients with systemic lupus erythematosus. Methods We used liquid chromatography tandem mass spectrometry to measure the levels of 27 sphingolipids in plasma from 107 female systemic lupus erythematosus patients and 23 controls selected using a design of experiment approach. We investigated the associations between sphingolipids and two disease activity indices, the Systemic Lupus Activity Measurement and the Systemic Lupus Erythematosus Disease Activity Index. Damage was scored according to the Systemic Lupus International Collaborating Clinics damage index. Renal activity was evaluated with the British Island Lupus Activity Group index. The effects of immunosuppressive treatment on sphingolipid levels were evaluated before and after treatment in 22 female systemic lupus erythematosus patients with active disease. Results Circulating sphingolipids from the ceramide and hexosylceramide families were increased, and sphingoid bases were decreased, in systemic lupus erythematosus patients compared to controls. The ratio of C 16:0 -ceramide to sphingosine-1-phosphate was the best discriminator between patients and controls, with an area under the receiver-operating curve of 0.77. The C 16:0 -ceramide to sphingosine-1-phosphate ratio was associated with ongoing disease activity according to the Systemic Lupus Activity Measurement and the Systemic Lupus Erythematosus Disease Activity Index, but not with accumulated damage according to the Systemic Lupus International Collaborating Clinics Damage Index. Levels of C 16:0 - and C 24:1 -hexosylceramides were able to discriminate patients with current versus inactive/no renal involvement. All dysregulated sphingolipids were normalized after immunosuppressive treatment. Conclusion We provide evidence that sphingolipids are dysregulated in systemic lupus erythematosus and associated with disease activity. This study demonstrates the utility of simultaneously targeting multiple components of a pathway to establish disease associations." @default.
• W2581330967 created "2017-02-03" @default.
• W2581330967 creator A5000606716 @default.
• W2581330967 creator A5001681126 @default.
• W2581330967 creator A5027609802 @default.
• W2581330967 creator A5029007706 @default.
• W2581330967 creator A5029557095 @default.
• W2581330967 creator A5037276492 @default.
• W2581330967 creator A5053954343 @default.
• W2581330967 creator A5054438024 @default.
• W2581330967 creator A5067367193 @default.
• W2581330967 creator A5083447947 @default.
• W2581330967 creator A5084408140 @default.
• W2581330967 date "2017-01-29" @default.
• W2581330967 modified "2023-10-01" @default.
• W2581330967 title "Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study" @default.
• W2581330967 cites W1850582709 @default.
• W2581330967 cites W1892855035 @default.
• W2581330967 cites W1965683411 @default.
• W2581330967 cites W1966452335 @default.
• W2581330967 cites W1967992422 @default.
• W2581330967 cites W1972686602 @default.
• W2581330967 cites W1988829041 @default.
• W2581330967 cites W1993918137 @default.
• W2581330967 cites W200450691 @default.
• W2581330967 cites W2009503588 @default.
• W2581330967 cites W2016032140 @default.
• W2581330967 cites W2033843051 @default.
• W2581330967 cites W2035526955 @default.
• W2581330967 cites W2037320159 @default.
• W2581330967 cites W2047634083 @default.
• W2581330967 cites W2056076387 @default.
• W2581330967 cites W2060320569 @default.
• W2581330967 cites W2064999867 @default.
• W2581330967 cites W2065094485 @default.
• W2581330967 cites W2067166961 @default.
• W2581330967 cites W2080718497 @default.
• W2581330967 cites W2087559924 @default.
• W2581330967 cites W2096687027 @default.
• W2581330967 cites W2098430088 @default.
• W2581330967 cites W2108905161 @default.
• W2581330967 cites W2113081845 @default.
• W2581330967 cites W2117065593 @default.
• W2581330967 cites W2129689703 @default.
• W2581330967 cites W2146203649 @default.
• W2581330967 cites W2158353135 @default.
• W2581330967 cites W2167876561 @default.
• W2581330967 cites W4244540082 @default.
• W2581330967 doi "https://doi.org/10.1177/0961203316686707" @default.
• W2581330967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28134039" @default.
• W2581330967 hasPublicationYear "2017" @default.
• W2581330967 type Work @default.
• W2581330967 sameAs 2581330967 @default.
• W2581330967 citedByCount "32" @default.
• W2581330967 countsByYear W25813309672018 @default.
• W2581330967 countsByYear W25813309672019 @default.
• W2581330967 countsByYear W25813309672020 @default.
• W2581330967 countsByYear W25813309672021 @default.
• W2581330967 countsByYear W25813309672022 @default.
• W2581330967 countsByYear W25813309672023 @default.
• W2581330967 crossrefType "journal-article" @default.
• W2581330967 hasAuthorship W2581330967A5000606716 @default.
• W2581330967 hasAuthorship W2581330967A5001681126 @default.
• W2581330967 hasAuthorship W2581330967A5027609802 @default.
• W2581330967 hasAuthorship W2581330967A5029007706 @default.
• W2581330967 hasAuthorship W2581330967A5029557095 @default.
• W2581330967 hasAuthorship W2581330967A5037276492 @default.
• W2581330967 hasAuthorship W2581330967A5053954343 @default.
• W2581330967 hasAuthorship W2581330967A5054438024 @default.
• W2581330967 hasAuthorship W2581330967A5067367193 @default.
• W2581330967 hasAuthorship W2581330967A5083447947 @default.
• W2581330967 hasAuthorship W2581330967A5084408140 @default.
• W2581330967 hasConcept C126322002 @default.
• W2581330967 hasConcept C159654299 @default.
• W2581330967 hasConcept C170493617 @default.
• W2581330967 hasConcept C190283241 @default.
• W2581330967 hasConcept C203014093 @default.
• W2581330967 hasConcept C2775915377 @default.
• W2581330967 hasConcept C2776912625 @default.
• W2581330967 hasConcept C2777851122 @default.
• W2581330967 hasConcept C2778674544 @default.
• W2581330967 hasConcept C2778703144 @default.
• W2581330967 hasConcept C2779134260 @default.
• W2581330967 hasConcept C55493867 @default.
• W2581330967 hasConcept C61705674 @default.
• W2581330967 hasConcept C71924100 @default.
• W2581330967 hasConcept C86803240 @default.
• W2581330967 hasConceptScore W2581330967C126322002 @default.
• W2581330967 hasConceptScore W2581330967C159654299 @default.
• W2581330967 hasConceptScore W2581330967C170493617 @default.
• W2581330967 hasConceptScore W2581330967C190283241 @default.
• W2581330967 hasConceptScore W2581330967C203014093 @default.
• W2581330967 hasConceptScore W2581330967C2775915377 @default.
• W2581330967 hasConceptScore W2581330967C2776912625 @default.
• W2581330967 hasConceptScore W2581330967C2777851122 @default.
• W2581330967 hasConceptScore W2581330967C2778674544 @default.
• W2581330967 hasConceptScore W2581330967C2778703144 @default.
• W2581330967 hasConceptScore W2581330967C2779134260 @default.

• next